{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:40:21Z","timestamp":1792809621643,"version":"4.5.0"},"reference-count":52,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The management of non-Hodgkin lymphoma is complicated by wide heterogeneity within recognized subtypes. Patients with supposedly similar diagnoses can have remarkably varied clinical presentations, molecular profiles and clinical outcomes. Reliable prognostic markers could allow the identification of patient subsets that may benefit from alternate approaches. Historically, a large number of clinical and molecular prognostic factors have been elucidated. However, the recent introduction of new therapies such as monoclonal antibodies has revolutionized treatment practices and greatly improved outcomes. This has called into question the value of previously recognized prognostic factors that need to be revalidated in the era of immunochemotherapy. It would appear that the commonly used clinical indices (IPI and FLIPI) retain predictive capacity, although they may have limited ability to identify a very poor outcome group. Currently there are no molecular markers that have been revalidated and shown to retain significance in the setting of current treatment practices for diffuse large B-cell lymphoma or follicular lymphoma. The biologic insights provided by molecular studies should allow for more targeted therapies to be developed, which will increase treatment choice and the possibility of tailored therapy in the future. It is imperative that future steps forward be made in the context of well-designed clinical trials with prospective correlative studies of clinical and biologic markers. This will allow us to continuously assess outcome predictors in the context of treatment change and to rationally design tailored treatment algorithms.<\/jats:p>","DOI":"10.1182\/asheducation-2006.1.295","type":"journal-article","created":{"date-parts":[[2006,11,22]],"date-time":"2006-11-22T23:14:02Z","timestamp":1164237242000},"page":"295-302","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":35,"title":["Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma"],"prefix":"10.1182","volume":"2006","author":[{"given":"Laurie H.","family":"Sehn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111707334986900_R1","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001."},{"key":"2019111707334986900_R2","doi-asserted-by":"crossref","unstructured":"Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 2005;23:4117\u20134126.","DOI":"10.1200\/JCO.2005.09.131"},{"key":"2019111707334986900_R3","doi-asserted-by":"crossref","unstructured":"Habermann T, Weller E, Morrison VA, et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): An update. J Clin Oncol. 2006: 3121\u20133127.","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"2019111707334986900_R4","doi-asserted-by":"crossref","unstructured":"Pfreundschuh M, Kloess M, Schmits R, et al. Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma: Results of the RICOVER-60 trial of the German High-grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2005;106:9a.","DOI":"10.1182\/blood.V106.11.13.13"},{"key":"2019111707334986900_R5","doi-asserted-by":"crossref","unstructured":"Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379\u2013391.","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"2019111707334986900_R6","doi-asserted-by":"crossref","unstructured":"Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027\u20135033.","DOI":"10.1200\/JCO.2005.09.137"},{"key":"2019111707334986900_R7","doi-asserted-by":"crossref","unstructured":"Project TIN-HsLPF. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987\u2013994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"2019111707334986900_R8","doi-asserted-by":"crossref","unstructured":"Sehn LH, Chhanabhai M, Fitzgerald C, et al. Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab and CHOP (R-CHOP). Blood. 2005;106:147a.","DOI":"10.1182\/blood.V106.11.492.492"},{"key":"2019111707334986900_R9","doi-asserted-by":"crossref","unstructured":"Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:995\u20131007.","DOI":"10.1200\/JCO.2005.02.4786"},{"key":"2019111707334986900_R10","doi-asserted-by":"crossref","unstructured":"Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood. 2005;106:1164\u20131174.","DOI":"10.1182\/blood-2005-02-0687"},{"key":"2019111707334986900_R11","doi-asserted-by":"crossref","unstructured":"Gascoyne RD. Emerging prognostic factors in diffuse large B cell lymphoma. Curr Opin Oncol. 2004;16:436\u2013441.","DOI":"10.1097\/00001622-200409000-00004"},{"key":"2019111707334986900_R12","doi-asserted-by":"crossref","unstructured":"Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2\u2013associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101:4279\u20134284.","DOI":"10.1182\/blood-2002-11-3442"},{"key":"2019111707334986900_R13","unstructured":"Wilson W, Pittaluga S, O\u2019Connor P, et al. Rituximab may overcome BCL-2-associated chemotherapy resistance in untreated DLBCL. Blood. 2001;98:343a."},{"key":"2019111707334986900_R14","doi-asserted-by":"crossref","unstructured":"Wilson K, Sehn LH, Berry B, et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in DLBCL. Proc Annu Meet Am Soc Clin Oncol. 2004;23:562a.","DOI":"10.1200\/jco.2004.22.14_suppl.6526"},{"key":"2019111707334986900_R15","doi-asserted-by":"crossref","unstructured":"Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006;107:4207\u20134213.","DOI":"10.1182\/blood-2005-10-4222"},{"key":"2019111707334986900_R16","doi-asserted-by":"crossref","unstructured":"Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u2013511.","DOI":"10.1038\/35000501"},{"key":"2019111707334986900_R17","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937\u20131947.","DOI":"10.1056\/NEJMoa012914"},{"key":"2019111707334986900_R18","doi-asserted-by":"crossref","unstructured":"Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68\u201374.","DOI":"10.1038\/nm0102-68"},{"key":"2019111707334986900_R19","doi-asserted-by":"crossref","unstructured":"Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2004.","DOI":"10.1182\/blood-2004-07-2947"},{"key":"2019111707334986900_R20","doi-asserted-by":"crossref","unstructured":"Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003;101:78\u201384.","DOI":"10.1182\/blood-2002-04-1286"},{"key":"2019111707334986900_R21","doi-asserted-by":"crossref","unstructured":"Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275\u2013282.","DOI":"10.1182\/blood-2003-05-1545"},{"key":"2019111707334986900_R22","doi-asserted-by":"crossref","unstructured":"Saez AI, Saez AJ, Artiga MJ, et al. Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol. 2004;164:613\u2013622.","DOI":"10.1016\/S0002-9440(10)63150-1"},{"key":"2019111707334986900_R23","doi-asserted-by":"crossref","unstructured":"Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350:1828\u20131837.","DOI":"10.1056\/NEJMoa032520"},{"key":"2019111707334986900_R24","doi-asserted-by":"crossref","unstructured":"Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:961\u2013968.","DOI":"10.1200\/JCO.2005.03.4264"},{"key":"2019111707334986900_R25","doi-asserted-by":"crossref","unstructured":"Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin\u2019s lymphoma. Ann Oncol. 2002;13:1356\u20131363.","DOI":"10.1093\/annonc\/mdf256"},{"key":"2019111707334986900_R26","unstructured":"Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin\u2019s disease. J Nucl Med. 2002;43:1018\u20131027."},{"key":"2019111707334986900_R27","doi-asserted-by":"crossref","unstructured":"Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376\u20131381.","DOI":"10.1182\/blood-2005-01-0272"},{"key":"2019111707334986900_R28","doi-asserted-by":"crossref","unstructured":"Dupuis J, Gaulard P, Itti E, et al. Early response evaluation with 18FDG-PET Scanning, but not phenotypic profile, are predictive of outcome in diffuse large B-cell lymphoma. Blood. 2005;106:543a.","DOI":"10.1182\/blood.V106.11.1914.1914"},{"key":"2019111707334986900_R29","unstructured":"Al-Tourah A, Chhanabhai M, Gill K, et al. Incidence, predictive factors and outcome of transformed lymphoma: A population-based study from British Columbia. Ann Oncol. 2005;16:v64."},{"key":"2019111707334986900_R30","doi-asserted-by":"crossref","unstructured":"Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417\u20131423.","DOI":"10.1182\/blood-2004-08-3175"},{"key":"2019111707334986900_R31","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725\u20133732.","DOI":"10.1182\/blood-2005-01-0016"},{"key":"2019111707334986900_R32","doi-asserted-by":"crossref","unstructured":"Hochster HS, Weller E, Gascoyne RD, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma: Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood. 2005;106:106a.","DOI":"10.1182\/blood.V106.11.349.349"},{"key":"2019111707334986900_R33","doi-asserted-by":"crossref","unstructured":"Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447\u20138452.","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"2019111707334986900_R34","doi-asserted-by":"crossref","unstructured":"Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006;24:1582\u20131589.","DOI":"10.1200\/JCO.2005.03.3696"},{"key":"2019111707334986900_R35","doi-asserted-by":"crossref","unstructured":"Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258\u20131265.","DOI":"10.1182\/blood-2003-12-4434"},{"key":"2019111707334986900_R36","doi-asserted-by":"crossref","unstructured":"Perea G, Altes A, Montoto S, et al. Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol. 2005;16:1508\u20131513.","DOI":"10.1093\/annonc\/mdi269"},{"key":"2019111707334986900_R37","doi-asserted-by":"crossref","unstructured":"Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108:1504\u20131508.","DOI":"10.1182\/blood-2006-01-013367"},{"key":"2019111707334986900_R38","doi-asserted-by":"crossref","unstructured":"Ott G, Katzenberger T, Lohr A, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood. 2002;99:3806\u20133812.","DOI":"10.1182\/blood.V99.10.3806"},{"key":"2019111707334986900_R39","doi-asserted-by":"crossref","unstructured":"Ganti AK, Weisenburger DD, Smith LM, et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol. 2006;17:920\u2013927.","DOI":"10.1093\/annonc\/mdl039"},{"key":"2019111707334986900_R40","doi-asserted-by":"crossref","unstructured":"Winter JN, Gascoyne RD, Van Besien K. Low-grade lymphoma. Hematology (Am Soc Hematol Educ Program). 2004:203\u2013220.","DOI":"10.1182\/asheducation-2004.1.203"},{"key":"2019111707334986900_R41","doi-asserted-by":"crossref","unstructured":"Gascoyne RD. Hematopathology approaches to diagnosis and prognosis of indolent B-cell lymphomas. Hematology (Am Soc Hematol Educ Program). 2005:299\u2013306.","DOI":"10.1182\/asheducation-2005.1.299"},{"key":"2019111707334986900_R42","doi-asserted-by":"crossref","unstructured":"de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol. 2005;23:6358\u20136363.","DOI":"10.1200\/JCO.2005.26.856"},{"key":"2019111707334986900_R43","doi-asserted-by":"crossref","unstructured":"Johnson NA, Al-Tourah A, Horsman DE, Connors JM, Gascoyne RD. Insights into disease evolution of transformed follicular lymphoma derived from cytogenetics. Blood. 2005;106:180a.","DOI":"10.1182\/blood.V106.11.604.604"},{"key":"2019111707334986900_R44","doi-asserted-by":"crossref","unstructured":"Akasaka T, Lossos IS, Levy R. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood. 2003;102:1443\u20131448.","DOI":"10.1182\/blood-2002-08-2482"},{"key":"2019111707334986900_R45","doi-asserted-by":"crossref","unstructured":"Bilalovic N, Blystad AK, Golouh R, et al. Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma. Am J Clin Pathol. 2004;121:34\u201342.","DOI":"10.1309\/TNKL7GDC66R9WPV5"},{"key":"2019111707334986900_R46","doi-asserted-by":"crossref","unstructured":"Torlakovic E, Bilalovic N, Golouh R, Zidar A, Angel S. Prognostic significance of PU.1 in follicular lymphoma. J Pathol. 2006;209:352\u2013359.","DOI":"10.1002\/path.1986"},{"key":"2019111707334986900_R47","doi-asserted-by":"crossref","unstructured":"Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005;106:2169\u20132174.","DOI":"10.1182\/blood-2005-04-1565"},{"key":"2019111707334986900_R48","doi-asserted-by":"crossref","unstructured":"Husson H, Carideo EG, Neuberg D, et al. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood. 2002;99:282\u2013289.","DOI":"10.1182\/blood.V99.1.282"},{"key":"2019111707334986900_R49","doi-asserted-by":"crossref","unstructured":"Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159\u20132169.","DOI":"10.1056\/NEJMoa041869"},{"key":"2019111707334986900_R50","doi-asserted-by":"crossref","unstructured":"Glas AM, Kersten MJ, Delahaye LJ, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood. 2005;105:301\u2013307.","DOI":"10.1182\/blood-2004-06-2298"},{"key":"2019111707334986900_R51","doi-asserted-by":"crossref","unstructured":"Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005;23:2020\u20132027.","DOI":"10.1200\/JCO.2005.01.112"},{"key":"2019111707334986900_R52","doi-asserted-by":"crossref","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23:9067\u20139072.","DOI":"10.1200\/JCO.2004.01.0454"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/295\/1091404\/295_302ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/295\/1091404\/295_302ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T01:25:35Z","timestamp":1628126735000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2006\/1\/295\/19716\/Optimal-Use-of-Prognostic-Factors-in-NonHodgkin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2006.1.295","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}